Claims for Patent: 9,968,674

Summary for Patent: 9,968,674

Title:	Methods and compositions comprising a combination of a VEGF Trap and an anti-CTLA-4 antibody
Abstract:	The present invention provides pharmaceutical compositions comprising a VEGF antagonist and an anti-CTLA-4 antibody, and methods of use thereof. The compositions and methods of the present invention are useful for the treatment of cancers and other diseases and disorders in which anti-angiogenic therapies and/or targeted immune responses may be beneficial.
Inventor(s):	Ioffe; Ella (Bronx, NY), Lowy; Israel (Dobbs Ferry, NY), Thurston; Gavin (Briafcliff Manor, NY), Burova; Elena (Mount Kisco, NY)
Assignee:	REGENERON PHARMACEUTICALS, INC. (Tarrytown, NY)
Application Number:	15/026,460
Patent Claims:	1. A method for inhibiting or attenuating the growth of a tumor in a subject, the method, comprising: administering to the subject a therapeutically effective amount of a VEGF antagonist; and a therapeutically effective amount of an anti-CTLA-4 antibody, wherein the VEGF antagonist is a VEGF Trap comprising Ig-like domain 2 of VEGF1, Ig-like domain 3 of VEGFR2, and a multimerizing domain. 2. The method of claim 1, wherein the VEGF antagonist and the anti-CTLA-4 antibody are administered to the subject in separate dosage forms. 3. The method of claim 2, wherein the separate dosage forms are administered to the subject simultaneously. 4. The method of claim 2, wherein the separate dosage forms are administered to the subject sequentially. 5. The method of claim 1, wherein the VEGF antagonist and the anti-CTLA-4 antibody are administered to the subject in a single dosage form. 6. The method of claim 1 wherein the VEGF antagonist is administered to the subject intravenously or subcutaneously. 7. The method of claim 1 wherein the anti-CTLA-4 antibody is administered to the subject intravenously or subcutaneously. 8. The method of claim 1, wherein the VEGF Trap comprises (1) a VEGFR1 component comprising amino acids 27 to 129 of SEQ ID NO:2; (2) a VEGFR2 component comprising amino acids 130-231 of SEQ ID NO:2; and (3) a multimerization component comprising amino acids 232-457 of SEQ ID NO:2. 9. The method of claim 8, wherein the VEGF Trap comprises VEGFR1 R2-FcAC1 (a) encoded by the nucleic acid sequence of SEQ ID NO:1. 10. The method of claim 1, wherein the anti-CTLA-4 antibody is an antagonist antibody. 11. The method of claim 1, wherein the anti-CTLA-4 antibody is ipilimumab or tremelimumab. 12. A method for inhibiting or attenuating the growth of a tumor in a subject, comprising: administering to the subject a therapeutically effective amount of a VEGF trap comprising Ig-like domain 2 of VEGFR1, Ig-like domain 3 of VEGFR2, and a multimerizing domain; and a therapeutically effective amount of an anti-CTLA-4 antibody, wherein the VEGF antagonist and the anti-CTLA-4 antibody are administered to the subject by injection. 13. The method of claim 12, wherein the VEGF Trap comprises (1) a VEGFR1 component comprising amino acids 27 to 129 of SEQ ID NO:2; (2) a VEGFR2 component comprising amino acids 130-231 of SEQ ID NO:2; and (3) a multimerization component comprising amino acids 232-457 of SEQ ID NO:2. 14. The method of claim 13, wherein the VEGF Trap comprises VEGFR1 R2-FcAC1 (a) encoded by the nucleic acid sequence of SEQ ID NO:1. 15. The method of claim 12, wherein the anti-CTLA-4 antibody is an antagonist antibody. 16. The method of claim 12, wherein the anti-CTLA-4 antibody is ipilimumab or tremelimumab.

Details for Patent 9,968,674

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	03/25/2011		2039-02-26